THE EFFECTIVENESS OF BISOPROLOL IN PATIENTS WITH RHEUMATIC HEART DISEASE WITH CHRONIC HEART FAILURE

Abstract

After 3 months of treatment, the first group showed a decrease in proinflammatory cytokines TNF-alpha by 22.6%, interleukin-6 by 25.3%.In the second group, TNF-alpha decreased by 15.8%, interleukin-6 decreased by 18.1%.There were improvements in the clinical condition and quality of life, an increase in exercise tolerance. Bisoprolol is an effective drug for the treatment of rheumatic heart defects complicated by CHF II-III FC, having a beneficial effect on immunological parameters (reducing the amount of pro-inflammatory cytokines) and improving the quality of life.